$6.40
0.63%
Nasdaq, Sep 02, 10:11 pm CET
ISIN
US0396971071
Symbol
ARDX

Ardelyx, Inc. Stock price

$6.40
+2.01 45.79% 1M
+1.32 25.98% 6M
+1.33 26.23% YTD
+0.22 3.56% 1Y
+5.31 487.16% 3Y
+0.78 13.88% 5Y
-12.80 66.67% 10Y
-7.71 54.64% 20Y
Nasdaq, Closing price Tue, Sep 02 2025
+0.04 0.63%
ISIN
US0396971071
Symbol
ARDX
Industry

Key metrics

Basic
Market capitalization
$1.5b
Enterprise Value
$1.5b
Net debt
positive
Cash
$238.5m
Shares outstanding
241.0m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
4.0 | 4.0
EV/Sales
3.9 | 3.9
EV/FCF
negative
P/B
11.0
Financial Health
Equity Ratio
39.7%
Return on Equity
-22.5%
ROCE
-10.3%
ROIC
-20.1%
Debt/Equity
1.4
Financials (TTM | estimate)
Revenue
$386.2m | $389.8m
EBITDA
$-37.4m | $-57.1m
EBIT
$-39.6m | $-84.3m
Net Income
$-56.2m | $-87.3m
Free Cash Flow
$-55.7m
Growth (TTM | estimate)
Revenue
83.9% | 16.8%
EBITDA
35.2% | -120.3%
EBIT
33.1% | -201.0%
Net Income
13.2% | -123.8%
Free Cash Flow
35.0%
Margin (TTM | estimate)
Gross
84.8%
EBITDA
-9.7% | -14.7%
EBIT
-10.3%
Net
-14.5% | -22.4%
Free Cash Flow
-14.4%
More
EPS
$-0.2
FCF per Share
$-0.2
Short interest
11.1%
Employees
395
Rev per Employee
$840.0k
Show more

Is Ardelyx, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,011 stocks worldwide.

Ardelyx, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

18 Analysts have issued a Ardelyx, Inc. forecast:

16x Buy
89%
2x Hold
11%

Analyst Opinions

18 Analysts have issued a Ardelyx, Inc. forecast:

Buy
89%
Hold
11%

Financial data from Ardelyx, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
386 386
84% 84%
100%
- Direct Costs 58 58
98% 98%
15%
327 327
81% 81%
85%
- Selling and Administrative Expenses 308 308
55% 55%
80%
- Research and Development Expense 60 60
44% 44%
15%
-37 -37
35% 35%
-10%
- Depreciation and Amortization 2.29 2.29
39% 39%
1%
EBIT (Operating Income) EBIT -40 -40
33% 33%
-10%
Net Profit -56 -56
13% 13%
-15%

In millions USD.

Don't miss a Thing! We will send you all news about Ardelyx, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Ardelyx, Inc. Stock News

Neutral
GlobeNewsWire
9 days ago
WALTHAM, Mass., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced its participation in the following upcoming investor conferences: Citi Biopharma Back to School Summit Location: Boston, MAFireside...
Positive
Seeking Alpha
19 days ago
The share price of Ardelyx has finally broken the year-long downtrend after a strong second quarter earnings report. Ibsrela returned to stronger topline growth in Q2 and the company raised the full-year net sales guidance range for the product by $10 million at the mid-point. Xphozah is showing resilience post-Medicare access loss, with commercial sales stabilizing and the product seeing incre...
Positive
The Motley Fool
29 days ago
Ardelyx Q2 Revenue Jumps 33%
More Ardelyx, Inc. News

Company Profile

Ardelyx, Inc. is a biopharmaceutical company, which engages in the research, development and commercialization of medicine for the treatment of cardiorenal diseases. Its product portfolio includes tenapanor, which is an experimental medication that works exclusively in the gut and is in late-stage clinical development. The company was founded by Dominique Charmot, Peter G. Schultz, and Jean M. Frechet on October 17, 2007 and is headquartered in Fremont, CA.

Head office United States
CEO Mike Raab
Employees 395
Founded 2007
Website www.ardelyx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today